Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen, MariTide and bone density
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 billion from the company's market value.
Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density
On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc (NASDAQ:AMGN) stated the MariTide (maridebart cafraglutide,
Amgen Says No Link Between MariTide And Changes In Bone Mineral Density
Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes
13h
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
11h
Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?
Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...
BioPharma Dive
11h
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
pharmaphorum
10h
Amgen plays down safety concern with obesity candidate
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
Yahoo
13h
Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot
Amgen
stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone ...
STAT
1d
Pharmalittle: We’re reading about an Amgen data controversy, J&J suing the feds, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us ...
FierceBiotech
21h
Hidden data on obesity prospect wipe $12B off Amgen market cap
A hidden tab in an Excel spreadsheet published nine months ago has wiped $12 billion off
Amgen
’s market cap. The tab ...
14h
Amgen issues statement regarding MariTide Phase 1 data
Amgen (AMGN) issued the following statement on the MariTide Phase 1 data. “As previously stated, Amgen does not see an association ...
STAT
2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on
Amgen
’s lead obesity candidate — not yet verified — erased $12 billion in market value.
Hosted on MSN
16h
Amgen dismisses bone density concerns related to its new weight-loss drug
(Reuters) -
Amgen
said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, ...
16h
Signal Says Pharma Stock Selloff Should Be Over
Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
MariTide
NASDAQ
AstraZeneca
Eli Lilly and Company
Tezspire
Feedback